Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regeneron has presented positive data from a phase III clinical program designed to provide two separate demonstrations of efficacy for Interleukin-1 Trap with patients suffering from CAPS, a spectrum of rare inherited inflammatory conditions.
Subscribe to our email newsletter
The phase III program of the Interleukin-1 (IL-1) Trap included two studies. Both studies met their primary endpoints, which was a reduction in disease activity. The activity was measured using a composite symptom score composed of a daily evaluation of fever/chills, rash, fatigue, joint pain, and eye redness/pain. The first study had an approximately 85% reduction in their mean symptom score compared to an approximately 13% reduction in patients treated with placebo.
Regeneron plans to file a biologics license application with the FDA in the second quarter of 2007. The FDA has granted orphan drug status and fast track designation to the IL-1 Trap program.
“Many of my CAPS patients who participated in the trial described dramatic responses to this investigational therapy,” said Hal Hoffman, associate professor of Pediatrics and Medicine at the University of California.